Korean J Pancreas Biliary Tract.  2021 Oct;26(4):233-240. 10.15279/kpba.2021.26.4.233.

Novel Drug Screening Platform: Tumor Organoid

• Maeng JE
• Seo HY
• Kim SC
• Ku JL

• KMID: 2522024
• DOI: http://doi.org/10.15279/kpba.2021.26.4.233

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is known to be one of the most lethal cancers among all cancer types, with a relative 5-year survival rate of less than 8%. Currently, surgery is the only probable curative treatment for PDAC which is available for only 10-15% of the patients diagnosed with the cancer. Organoids resemble the original tissue in morphology and function with self-organizing capacity. Organoids can be cultured with high effectiveness from individual patient derived tumor tissue which makes them an extremely fitting model for translational uses and the improvement of personalized cancer medicine. Before personalized medicine based on organoids can be applied in the clinic, the improvement of drug screening platforms in terms of sensitivity and robustness is necessary.

Keyword

Pancreatic cancer; Organoids; Drug screening assays; Biobanking; Next generation sequencing; 췌장암; 오가노이드; 약물 스크리닝; 바이오뱅킹; 차세대 염기서열 분석